ClinicalTrials.gg

Program

LY4065967

A development code. Also written as “LY4065967 ISA”, “LY4065967 Tablet” and “LY4065967 Formulated Capsule”.

In Eli Lilly's pipeline, AT2R antagonist. Its studies are mostly in Osteoarthritis, Knee · Neuralgia · Chronic Pain, led by Eli Lilly.

Furthest: phase 2, since Aug 1, 20237 company-led studies, 4 open or runningNext primary completion: Apr 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly74 open or runningphase 2since Aug 1, 2023Aug 1, 2023Apr 2027phase 2 · NCT05986292
  • Named in Eli Lilly’s own pipeline as AT2R Antagonist, phase 2, as of Oct 29, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 1, 2023First study: phase 2 study in Osteoarthritis, KneeFirst studyNCT05986292 · 10,000 planned · United States, Puerto Rico
  2. Sep 10, 2024Phase 1 study in HealthyNCT06594159 · 59 enrolled · Japan
  3. Jun 19, 2025Phase 1 study in HealthyNCT07039045 · 16 enrolled · United States
  4. Dec 9, 2025Phase 2 study in Diabetic Peripheral Neuropathic PainNCT07285018 · 150 planned · United States, Puerto Rico
  5. May 19, 2026Phase 1 study in HealthyNCT07607483 · 36 enrolled · United States
  6. Jun 8, 20262 phase 2 studiesNCT07641517, NCT07641504

Ahead

  1. Apr 2027Primary completion: phase 2 study in Osteoarthritis, KneeNCT07641517
  2. Apr 2027Primary completion: phase 2 study in Chronic PainNCT07641504
  3. Apr 2027Primary completion: phase 2 study in Osteoarthritis, KneeNCT05986292
  4. Jul 2027Primary completion: phase 2 study in Diabetic Peripheral Neuropathic PainNCT07285018

TargetBeta

“AT2R antagonist”the company's pipeline, read by Claude · source

Other programs on AGTR2

ProgramCompanyFurthest phaseStudies
TRD205Sino Biopharmaceuticalphase 25

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07641517Osteoarthritis, Knee · United States, Puerto Rico2RecruitingApr 2027150
NCT07641504Chronic Pain · United States, Puerto Rico2RecruitingApr 2027150
NCT07607483Healthy · United States1CompletedJul 27, 202636
NCT07285018Diabetic Peripheral Neuropathic Pain · United States, Puerto Rico2RecruitingJul 2027150
NCT07039045Healthy · United States1CompletedAug 16, 202516
NCT06594159Healthy · Japan1CompletedMar 11, 202559
NCT05986292Osteoarthritis, Knee · United States, Puerto Rico2RecruitingApr 202710,000

How it is read

Names in the registry

  • “LY4065967”, 5 entries
  • “LY4065967 ISA”, 1 entry
  • “LY4065967 Tablet”, 1 entry
  • “LY4065967 Formulated Capsule”, 1 entry
  • “LY4065967 Capsule”, 1 entry

Codes read as this program: LY4065967.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.